Biomarkers for Invasive Mucormycosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-64
SponsorUniversity Hospital, Lille
About this trial
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization. Prompt initiation of adequate antifungal therapy is critical for treating mucormycosis. Early diagnostic is therefore essential. The presence in the Mucorales' cell wall of uncommon monosaccharides open interesting perspectives for the development of specific diagnostic biomarkers.
This study evaluate a diagnostic test for mucormycosis in a cohort of patients with MM and in control groups (high-risk patients without MM and patients with another IFI).
Eligibility criteria
Qualifiers
Men and women
Age : Children and adults from 3 to 64 years old (18 to 64 for controls)
In patients whose consent has been collected after information. In the case of children, information on the study will be given to the holders of parental authority and then to the child to obtain their consent.
Patient social insured
Disqualifiers
Patients for whom the inclusion criteria are not met
Co-infection mucormycosis/other IFI
Trial design
Treatments tested in this trial
- Venous sample
Treatment groups
100 Participants
are divided into 3 treatment groupsSponsors and collaborators
University Hospital, Lille
Lead sponsor
Plateforme PAGés, Analyses Glycoconjugués
Collaborator
Région Hauts de France, France
Collaborator
SATT Nord
Collaborator
Source ClinicalTrials.gov